✅ Purpose

• To reduce patient burden due to the increase in non-insurance-covered medications
• To offer revenue opportunities for medical institutions through private medical services
• To promote safe and legitimate access to Indian generic drugs in Japan

✅ Overall Structure (Three Pillars)

① Online Clinic Portal (Private Medical Services)

• Targets include ED, AGA, birth control pills, diet medications, and newly uninsured drugs (headache meds, patches, vitamins, etc.)
• Available to private clinics nationwide
• Doctors diagnose online → prescribe → provide Indian generics (or sell via ②/③)

Goals (Year 1):
Over 100 participating clinics
Over 5,000 monthly prescriptions
Expand brand awareness of “Onkuri JP”

② Affiliate EC Site for Doctors (with Pharmaceutical Certification)

• Import uninsured medicines from India with official doctor’s pharmaceutical certificates
• Affiliate links and QR codes are issued per doctor for patient access
• Patients import individually (accessible only via doctor referral)
• Doctors receive 10–15% sales margin

Benefits:
No inventory or risk for doctors
Affordable and safe medications for patients
Platform earns through scaled profit sharing

Goals (Year 1):
Over 300 registered doctors
Over 10,000 monthly orders
Over 30 items handled (headache, skin care, constipation, vitamins, allergy meds)

③ Our Direct Import EC Site (Private Only)

• Not publicly accessible (to comply with Japanese law)
• Available only to patients guided from clinics or the portal after diagnosis
• Focus on generics of uninsured drugs and common U.S. OTC medications
• Items include Excedrin-type headache meds, antihistamines, vitamins, beauty creams

Goals (Year 1):
Over 5,000 unique monthly buyers
Introduce subscription system to maximize LTV (e.g., discounted shipping plans)

✅ Revenue Model (Simplified)

✅ 5-Year Vision (Growth Strategy)

✅ Suggested Branding Direction

• Doctor-Only EC Site: “Doctor Yakuchoku”, “MediXplore”
• Online Clinic Portal: “Onkuri JP | Private Online Consultation Hub”
• Private Import EC Site: “YakuDirect JP”, “SecondMedi”

OTC-Equivalent Drug Exclusion from Japanese Health Insurance

Due to upcoming changes in Japan’s national health insurance policy, many commonly used prescription drugs with OTC-equivalent ingredients will be excluded from coverage by April 2025.

The Opportunity

• Drugs that used to cost 300 yen may rise to 1,000 yen out-of-pocket.
• Introducing Indian generics at around 500 yen through private practice creates a win-win-win situation for patients, clinics, and national healthcare cost.

Timeline

• April 2025 – Planned official implementation
• Final adjustments and decisions by MHLW and Chuikyo in 2024
• January 2025 – New NHI drug price list to be announced

Policy Background

• December 2023 – Government reform roadmap officially states gradual OTC-like drug exclusion starting in FY2025
• May 2024 onward – Specific ingredients and indications under review

Policy Details

Drugs that can be substituted with OTC equivalents will be removed from insurance eligibility. Examples include:

• Moisturizers (e.g., Heparinoid-based)
• Mild constipation or gastrointestinal drugs
• Allergy medications
• Vitamin supplements

Exceptions (Important)

Insurance may still apply under strict conditions:

• Severe cases (e.g., cancer, chronic diseases)
• Documented allergic reactions to OTC options
• Justification required on claim submission

List of Commonly Used Drugs Affected

Conclusion

• Starting April 2025, a broad list of mild-symptom prescription drugs will be excluded from NHI coverage
• Out-of-pocket cost will jump 3–5x for affected patients
• Indian generics offered via online consultation or certified clinics are a viable and scalable alternative

oncli.jp｜Oncli JP